Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK study of subcutaneous Anktiva in healthy volunteers
NCT03381586Phase 1Completed
- Sponsor
- Altor BioScience Corporation
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nogapendekin alfa inbakicept in bladder cancer (2 arms), sponsored by Altor BioScience Corporation. Primary endpoints: Half-life up to 192 hours, Apparent Volume of Distribution up to 192 hours and 5 more. Started Dec 2017; status: completed.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03381586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381586.